SERUM AUTOANTIBODIES MULTI-TESTING IN RHEUMATOID ARTHRITIS IN PRIMARY CARE CAN REDUCE AVOIDABLE COSTS ASSOCIATED TO FALSE POSITIVES. A SIMULATION STUDY IN THE UNITED STATES OF AMERICA

Author(s)

Mascialino B1, Swiniarski S2, Gehring I2, Poorafshar M1, Tarrant T3
1Thermo Fisher Scientific, Uppsala, Sweden, 2Thermo Fisher Scientific, Freiburg, Germany, 3Duke School of Medicine, Durham, NC, USA

OBJECTIVES

: Rheumatoid arthritis (RA) diagnosis requires a combination of clinical, laboratory and imaging investigations. The consequences of wrong serology test results are costly: False Positive results (FPs) are initially managed as RA-patients, bringing about extra costs until correct diagnosis is made.

The study goals were to:

  • simulate the diagnostic performance of Rheumatoid Factor (RF)-IgA, RF-IgM, and cyclic citrullinated peptides (CCP2), used alone or in multi-testing parallel/sequential combinations;
  • quantify the economic consequences of serology FPs in the United States.
METHODS A 12-month Markov model simulated 500,000 RA-suspected individuals tested in Primary Care with mono- or multi-testing. Costs came from the published literature. Uncertainty was addressed with sensitivity analysis.

RESULTS

: The mono-testing diagnostic performance was:

Conference/Value in Health Info

2018-05, ISPOR 2018, Baltimore, MD, USA

Value in Health, Vol. 21, S1 (May 2018)

Code

PMD8

Topic

Epidemiology & Public Health

Topic Subcategory

Disease Classification & Coding

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×